Jazz Pharmaceuticals plans U.S. launch of Ziihera.
5 reports, 3 independent
Updated Sep 20
No new developments lately
- Reports
- 5
- Developments
- 3
- Repetition
- 40%
New informationRepeats or wire copies
AI-generated analysis. Brind wrote this summary from the reports listed below. It can be wrong. Each section says how much you can rely on it, and the sources are linked so you can check.
What happened
Jazz Pharmaceuticals plans U.S. launch of Ziihera.
Who's involved
What this event is mainly aboutHow it developed
Newest first. Tap a step to see who reported it.Zymeworks provides proprietary technology to Jazz Pharmaceuticals for Ziihera commercialization.1 source
FDA grants approval for Ziihera, enabling its market introduction.1 source
U.S. launch plans for Ziihera.1 source
Keep exploring
The entities involved
-
Jazz Pharmaceuticals
Irish tax-registered pharmaceutical corporation
Related events
- Jazz Pharmaceuticals guaranteed notes issued by its subsidiary, Jazz Investments I Limited, on August 26, 2026.
- The California State Teachers Retirement System has increased its stake in Jazz Pharmaceuticals.
- Jazz Pharmaceuticals received FDA approval for a drug following positive clinical trial results.
- Jazz Pharmaceuticals and RYTHM are competing in the pharmaceutical market and listed on the Nasdaq stock exchange.